(Q42924102)

11 November 2017

title

A new method for examining the cost savings of reducing COPD exacerbations (English)

1 reference

11 November 2017

A New Method for Examining the Cost Savings of Reducing COPD Exacerbations (English)

1 reference

https://api.crossref.org/works/10.2165/11535600-000000000-00000

2 July 2024

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20799755

2 July 2024

author name string

Michael Schum

2

1 reference

11 November 2017

Eva Lydick

3

1 reference

11 November 2017

Douglas W. Mapel

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20799755

2 July 2024

Jeno P. Marton

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20799755

2 July 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20799755

2 July 2024

publication date

1 January 2010

1 reference

11 November 2017

1 reference

11 November 2017

volume

28

1 reference

11 November 2017

issue

9

1 reference

11 November 2017

page(s)

733-749

1 reference

https://scigraph.springernature.com/pub.10.2165/11535600-000000000-00000

11 November 2017

exact match

0 references

cites work

The addition of salmeterol 50 microg bid to anticholinergic treatment in patients with COPD: a randomized, placebo controlled trial. Chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.2165%2F11535600-000000000-00000

Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11535600-000000000-00000

Use of a long-acting inhaled beta2-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11535600-000000000-00000

Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11535600-000000000-00000

Cost-effectiveness of combination therapy for chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11535600-000000000-00000

Resource use study in COPD (RUSIC): a prospective study to quantify the effects of COPD exacerbations on health care resource use among COPD patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11535600-000000000-00000

One-year cost-effectiveness of tiotropium versus ipratropium to treat chronic obstructive pulmonary disease.

21 January 2018

1 reference

12 December 2020

The cost of moderate and severe COPD exacerbations to the Canadian healthcare system

1 reference

12 December 2020

Probabilistic Markov model to assess the cost-effectiveness of bronchodilator therapy in COPD patients in different countries.

1 reference

12 December 2020

Resource use and risk factors in high-cost exacerbations of COPD.

1 reference

12 December 2020

Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial

1 reference

12 December 2020

Medicare and cost-effectiveness analysis

1 reference

12 December 2020

Cost effectiveness of inhaled steroid withdrawal in outpatients with chronic obstructive pulmonary disease

1 reference

12 December 2020

Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. International COPD Study Group.

1 reference

12 December 2020

Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium

1 reference

12 December 2020

Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease

1 reference

12 December 2020

Economic assessment of initial maintenance therapy for chronic obstructive pulmonary disease.

1 reference

12 December 2020

Toward a consensus definition for COPD exacerbations

1 reference

12 December 2020

COPD exacerbations: the importance of a standard definition

1 reference

12 December 2020

Healthcare costs of COPD in Italian referral centres: a prospective study.

1 reference

12 December 2020

Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial

1 reference

12 December 2020

Assessing treatment effects of inhaled corticosteroids on medical expenses and exacerbations among COPD patients: longitudinal analysis of managed care claims.

1 reference

12 December 2020

Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease

1 reference

12 December 2020

Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD

1 reference

12 December 2020

Cost effectiveness of budesonide/formoterol in a single inhaler for COPD compared with each monocomponent used alone

1 reference

12 December 2020

Cost-effectiveness of fluticasone propionate/salmeterol (500/50 microg) in the treatment of COPD.

1 reference

12 December 2020

The costs of exacerbations in chronic obstructive pulmonary disease (COPD).

1 reference

12 December 2020

Evaluating the pharmacoeconomic effect of adding tiotropium bromide to the management of chronic obstructive pulmonary disease patients in Singapore

1 reference

12 December 2020

Cost-effectiveness of salmeterol in patients with chronic obstructive pulmonary disease: an economic evaluation

1 reference

12 December 2020

The role of long-acting bronchodilators in the management of stable COPD.

1 reference

12 December 2020

Modelling the 5-year cost effectiveness of tiotropium, salmeterol and ipratropium for the treatment of chronic obstructive pulmonary disease in Spain

1 reference

12 December 2020

A computer simulation model of the natural history and economic impact of chronic obstructive pulmonary disease

1 reference

12 December 2020

Inhaled corticosteroids and the risk of a first exacerbation in COPD patients

1 reference

12 December 2020

Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease

1 reference

12 December 2020

An appraisal of pharmacoeconomic evidence of maintenance therapy for COPD.

1 reference

12 December 2020

Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper

1 reference

12 December 2020

Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial

1 reference

12 December 2020

Economic evaluation of tiotropium and salmeterol in the treatment of chronic obstructive pulmonary disease (COPD) in Greece.

1 reference

12 December 2020

Cost effectiveness of therapy with combinations of long acting bronchodilators and inhaled steroids for treatment of COPD.

1 reference

12 December 2020

Economic benefits of self-management education in COPD.

1 reference

12 December 2020

Obtaining evidence for use by healthcare payers on the success of chronic obstructive pulmonary disease management

1 reference

12 December 2020

Trends and cardiovascular co-morbidities of COPD patients in the Veterans Administration Medical System, 1991-1999.

1 reference

12 December 2020

Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease

1 reference

12 December 2020

A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease

1 reference

12 December 2020

Prediction of risk of COPD exacerbations by the BODE index.

1 reference

12 December 2020

Risk indexes for exacerbations and hospitalizations due to COPD

1 reference

12 December 2020

The direct medical costs of undiagnosed chronic obstructive pulmonary disease

1 reference

12 December 2020

Healthcare costs with tiotropium plus usual care versus usual care alone following 1 year of treatment in patients with chronic obstructive pulmonary disorder (COPD).

1 reference

12 December 2020

The costs of treating COPD in the United States

1 reference

12 December 2020

The impact of severe exacerbations on quality of life and the clinical course of chronic obstructive pulmonary disease

1 reference

12 December 2020

Addressing resource allocation issues in recommendations from clinical practice guideline panels: suggestions from an American College of Chest Physicians task force

1 reference

12 December 2020

Cost-effectiveness of fluticasone propionate in the treatment of chronic obstructive pulmonary disease: a double-blind randomized, placebo-controlled trial

1 reference

12 December 2020

Predicting the costs of managing patients with chronic obstructive pulmonary disease

1 reference

12 December 2020

Health care utilization in chronic obstructive pulmonary disease. A case-control study in a health maintenance organization

1 reference

12 December 2020

Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases

1 reference

12 December 2020

Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease

1 reference

12 December 2020

An economic assessment of inhaled formoterol dry powder versus ipratropium bromide pressurized metered dose inhaler in the treatment of chronic obstructive pulmonary disease

1 reference

12 December 2020

Contemporary management of chronic obstructive pulmonary disease: scientific review

1 reference

12 December 2020

Efficacy of salmeterol xinafoate in the treatment of COPD

1 reference

12 December 2020

The effect of tiotropium on exacerbations and airflow in patients with COPD.

1 reference

12 December 2020

Addition of salmeterol to existing treatment in patients with COPD: a 12 month study

1 reference

12 December 2020

Effect of fluticasone propionate/salmeterol (250/50 microg) or salmeterol (50 microg) on COPD exacerbations

1 reference

12 December 2020

Information on cost-effectiveness: an essential product of a national comparative effectiveness program

1 reference

12 December 2020

Estimating the cost-effectiveness of fluticasone propionate for treating chronic obstructive pulmonary disease in the presence of missing data

1 reference

12 December 2020

Annals of Internal Medicine

9

148

957

2008

1 reference

https://api.crossref.org/works/10.2165/11535600-000000000-00000

Utilization in COPD: patient characteristics and diagnostic evaluation

2 July 2024

34

1 reference

https://api.crossref.org/works/10.2165/11535600-000000000-00000

2 July 2024

Identifiers

1 reference

Dimensions Publication ID

11 November 2017

1036667142

0 references

1 reference